Here’s a startling fact: Liver cancer patients who receive a specific type of treatment after immunotherapy may live significantly longer than those who don’t. But here’s where it gets controversial—this life-extending approach, known as curative treatment conversion (CTC), is still not widely adopted, despite its promising results. Why is this the case, and what does it mean for patients battling hepatocellular carcinoma (HCC)? Let’s dive in.
A recent study published in Liver Cancer sheds light on this underutilized strategy. Among 4,765 HCC patients, only 3.2% (138 individuals) received curative therapy following immunotherapy. These treatments included surgical resection (54.3%), local ablation (25.4%), and liver transplantation (20.3%). And this is the part most people miss—compared to the 4,101 patients who didn’t receive CTC, those who did experienced dramatically improved overall survival rates (HR, 0.15; 95% CI, 0.11-0.22; P <.001). The most significant survival benefits were seen in patients who underwent resection, followed by transplantation and ablation.
But what makes CTC so effective? According to multivariate analysis, CTC independently correlated with better survival outcomes (HR, 0.20; 95% CI, 0.11-0.37; P <.001). Interestingly, receiving treatment at an academic center also played a crucial role (HR, 0.70; 95% CI, 0.59-0.82; P <.001). This raises a thought-provoking question: Are academic centers better equipped to offer CTC, or is there something else at play? Is this a matter of access, expertise, or both?
Dr. Ju Dong Yang, senior study author and medical director of the Liver Cancer Program at Cedars-Sinai, highlights the paradox: “Performing liver transplant following immunotherapy isn’t yet common practice, which is unfortunate. Patients with advanced liver cancer often die from other liver ailments, even if their cancer is under control. A transplant gives them a healthy liver and a chance at longer life.” This statement underscores the urgency of reevaluating current treatment protocols.
The study, which analyzed data from the US National Cancer Database between 2017 and 2020, also revealed demographic and clinical differences between patients who received CTC and those who didn’t. Patients in the CTC group were younger (median age 63 vs. 66), had smaller tumors (57 mm vs. 75 mm), and were more likely to be treated at academic centers (78% vs. 48%). But here’s the kicker—even after adjusting for these factors, CTC remained a strong predictor of improved survival, suggesting its potential as a game-changer in HCC treatment.
So, why isn’t CTC more widely adopted? The study hints at barriers like limited access to academic centers and the complexity of coordinating multi-step treatments. Is the medical community overlooking a lifesaving opportunity, or are there valid reasons for the slow adoption of CTC? We’d love to hear your thoughts in the comments.
As Dr. Robert Figlin, interim director of Cedars-Sinai Cancer, aptly puts it, “When physician-scientists design studies based on patient needs and apply their findings to care, it improves outcomes for everyone.” This study is a testament to that mission, but it also leaves us with a critical question: How can we make CTC more accessible to all liver cancer patients?
Stay informed about groundbreaking advances in cancer care—subscribe to our newsletter today and join the conversation.
